Summary

Our "Psoriasis - Competitive Landscape in 2020" combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Interleukin and tumor necrosis factor inhibitors are the major focus of drug developers. There are 350 drugs in the pipeline, 89% 0f which are in early-stage. Big pharma dominates R&D in this indication. Addition of several high-priced therapies are expected to drive the market growth, but emergence of biosimilars to all the marketed brands is expected to act as a strong barrier to market growth.

This reports provides a data-driven overview of the current and future competitive landscape in Psoriasis therapeutics.


Scope

Components of the report include -

  • Disease epidemiology
  • Marketed drugs assessment
  • Pipeline drugs assessment
  • Clinical trials assessment
  • Commercial assessment
  • Social media overview
  • Digital marketing overview




Reasons To Buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global psoriasis market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global psoriasis in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.